Cost–Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France

INTRODUCTION: The aim of the current study is to estimate the cost-effectiveness of adjuvant treatment with nivolumab relative to clinically relevant comparators in adult patients with melanoma with lymph node involvement or metastatic disease who have undergone complete resection from a French soci...

Descripción completa

Detalles Bibliográficos
Autores principales: Bregman, Bruno, Teitsson, Siguroli, Orsini, Isabella, Cotté, François-Emery, Amadi, Adenike, Moshyk, Andriy, Roze, Stéphane, Gaudin, Anne-Françoise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649185/
https://www.ncbi.nlm.nih.gov/pubmed/32920709
http://dx.doi.org/10.1007/s13555-020-00446-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649185/
https://www.ncbi.nlm.nih.gov/pubmed/32920709
http://dx.doi.org/10.1007/s13555-020-00446-z

Ejemplares similares